A minireview of CYP2C9 and CYP2C19 single nucleotide polymorphisms (SNPs) among Malaysian populations

Authors

  • Rasmaizatul Akma Rosdi Department of Paediatrics, School of Medical Sciences, Universiti Sains Malaysia (USM) (Health Campus), 16150 Kubang Kerian, Kelantan
  • Narazah Mohd Yusoff Advanced Medical and Dental Institute (AMDI), USM, 13200 Kepala Batas, Pulau Pinang
  • Rusli Ismail Faculty of Medicine, Universiti Sultan Zainal Abidin (UniSZA), Medical Campus, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Terengganu
  • Tan Soo Choon Institute for Research in Molecular Medicine (INFORMM), USM, Jalan Inovasi, 11800 Gelugor, Pulau Pinang
  • Nurfadhlina Musa INFORMM, USM (Health Campus), 16150 Kubang Kerian, Kelantan
  • Surini Yusoff Department of Paediatrics, School of Medical Sciences, USM (Health Campus), 16150 Kubang Kerian, Kelantan

Keywords:

pharmacogenetics, cytochrome P450, CYP2C9 gene, CYP2C19 gene, Malaysian population, allele frequency, personalized medicine

Abstract

It has been recognized extensively that studies of pharmacogenetics provide massive examples of causal relationship between genotypes and drug effectiveness to account for interindividual phenotypic variations in drug therapy. In most cases, cytochrome P450 (CYP) polymorphisms are one of the major variables that affecting those drug plasma concentration, drug detoxification and drug activation in humans. Thus, understanding of CYP polymorphisms can be crucially valuable in order to allow early and more accurate drug dosage prediction and improve the drug response accordingly. Despite the high level of homologous amino acid sequences, CYP2C9 and CYP2C19 genes are among the most important CYP genes which metabolize a wide range of clinically therapeutic drugs. Several critical reviews have been published relating to the aforementioned genes. However, this minireview aims to systematically merge reported studies on the SNPs frequencies of both genes concentrating only on Malaysian population. It is hoped that, the minireview can be an opener for new opportunities to reevaluate the evidence on the prevalence of CYP2C genes as a potential genetic factor influencing a particular drug efficacy and safety among Malaysian. Such evaluation can be developed to the next level of early prediction of better and specific drug treatment, thereby improving the drug response while helping the government in minimising the drug expenditures.

References

Ishikawa T, Tsuji A, Inui K, Sai Y, Anzai N, et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics. 2004; 5(1):pp.67-99.

De Montellano O. Cytochrome P450: Structure, Mechanism and Biochemistry. New York; Springer, 2005.

Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007; 116:pp.496-526.

Wolf CR, Smith G. Pharmacogenetics. Br Med Bull. 1999; 55(2):pp.366-386.

Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002; 3:pp.561-597.

Demorais SM, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun. 1993; 194:pp.194-201.

Yang X, Zhang B, Molony C, Chudin E, Hao K, et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010; 20:pp.1020-1036.

Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C family. Pharmacogenetics. 1994; 4(6):pp.285-299.

Romkes M, Faletto MB, Blaisdell JA, Goldstein J. Cloning and Expression of Complementary DNAs for Multiple Members of the Human Cytochrome P450IIC Subfamily. 1991.

Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003; 17:pp.27-41.

Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, et al. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem. 2002; 277:pp.209-217.

Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998; 45(6):pp.525-538.

Lim JSL, Chen XA, Singh O, Yap YS, Ng RCH, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011; 71(5):pp.737-750.

Zainuddin Z, Teh LK, Suhaimi AWM, Ismail R. Malaysian Indians are genetically similar to Caucasians : CYP2C9 polymorphism. J Clin Pharm Ther. 2006; 31:pp.187-191.

Seng KC, Gin GG, Sangkar JV, Phipps ME. Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in Malaysia. Asian Pacific J Mol Biol Biotechnol. 2003; 11(2):pp.83-91.

Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol. 2003; 17:pp.373-376.

Yoon Y-R, Shon J-H, Kim M-K, Lim Y-C, Lee H-R, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol. 2001; 51:pp.277-280.

Miyuki K, Ichiro I, Kohsuke M, Akinori U, Shun H. Genetic polymorphisms of cytochrome P450s, CYP2C19 and CYP2C9 in a Japanese population. Ther Drug Monit. 1998; 20(3):pp.243-247.

Rosdi R, Mohd Yusoff N, Ismail R, Choon T, Saleem M, et al. High allele frequency of CYP2C9*3 (rs1057910) in a Negrito’s subtribe population in Malaysia; Aboriginal people of Jahai. Ann Hum Biol. 2015.

Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients : genetic analysis of the CYP2C9 locus. Pharmacogenetics. 2000; 10:pp.85-89.

Saab YB, Langaee T. Genetic polymorphisms of CYP2C9: Comparison of prevalence in the Lebanese population with other populations. Pharmacol Pharm. 2011; 2:pp.88-93.

Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJJ, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001; 60(2):pp.382-387.

Xie H-G, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants : ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002; 54:pp.1257-1270.

Rendic S, Di Carlo F. Human cytochrome P450 enzymes: a status report summarizng their actions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997; 29:pp.413-580.

Desta Z, Zhao X, Shin J-G, Flockhart DA. Clinical significance of the Cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41(12):pp.913-958.

Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009; 10(11):pp.1799-1817.

Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1):pp.103-113.

Hu L-M, Dai D-P, Hu G-X, Yang J-F, Xu R, et al. Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population. Pharmacogenomics. 2012; 13(14):pp.1571-1581.

Mejin M, Tiong WN, Lai LYH, Tiong LL, Bujang AM, et al. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. Int J Clin Pharm. 2013; 35(4):pp.621-628.

Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009; 19(2):pp.170-179.

Hitchen L. Adverse Drug Reactions Result in 250,000 UK Admissions a Year. Vol 332. 2006.

Downloads

Published

2017-07-24

Issue

Vol. 2 No. 1 (2017): June 2017

Section

Journal of Biomedical and Clinical Sciences

License

JBCS Publication Ethics

JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.

Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.

Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.

This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.

Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.

Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.

In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).

Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors  without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.

CONFLICT OF INTEREST

Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.

Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.

HUMAN AND ANIMAL RIGHTS

All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.

Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.

Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.

A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.

INFORMED CONSENT

For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.

DATA SHARING POLICY

JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible

Authors who do not wish to share their data must state that data will not be shared, and give the reason.

COPYRIGHT NOTICE

The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.

While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.